image_2_Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer.tiff
Surfactant protein D (SP-D) is a pattern recognition molecule belonging to the Collectin (collagen-containing C-type lectin) family that has pulmonary as well as extra-pulmonary existence. In the lungs, it is a well-established opsonin that can agglutinate a range of microbes, and enhance their clearance via phagocytosis and super-oxidative burst. It can interfere with allergen–IgE interaction and suppress basophil and mast cell activation. However, it is now becoming evident that SP-D is likely to be an innate immune surveillance molecule against tumor development. SP-D has been shown to induce apoptosis in sensitized eosinophils derived from allergic patients and a leukemic cell line via p53 pathway. Recently, SP-D has been shown to suppress lung cancer progression via interference with the epidermal growth factor signaling. In addition, a truncated form of recombinant human SP-D has been reported to induce apoptosis in pancreatic adenocarcinoma via Fas-mediated pathway in a p53-independent manner. To further establish a correlation between SP-D presence/levels and normal and cancer tissues, we performed a bioinformatics analysis, using Oncomine dataset and the survival analysis platforms Kaplan–Meier plotter, to assess if SP-D can serve as a potential prognostic marker for human lung cancer, in addition to human gastric, breast, and ovarian cancers. We also analyzed immunohistochemically the presence of SP-D in normal and tumor human tissues. We conclude that (1) in the lung, gastric, and breast cancers, there is a lower expression of SP-D than normal tissues; (2) in ovarian cancer, there is a higher expression of SP-D than normal tissue; and (3) in lung cancer, the presence of SP-D could be associated with a favorable prognosis. On the contrary, at non-pulmonary sites such as gastric, breast, and ovarian cancers, the presence of SP-D could be associated with unfavorable prognosis. Correlation between the levels of SP-D and overall survival requires further investigation. Our analysis involves a large number of dataset; therefore, any trend observed is reliable. Despite apparent complexity within the results, it is evident that cancer tissues that produce less levels of SP-D compared to their normal tissue counterparts are probably less susceptible to SP-D-mediated immune surveillance mechanisms via infiltrating immune cells.
History
References
- https://doi.org//10.1016/S0304-4165(02)00320-3
- https://doi.org//10.3389/fimmu.2012.00131
- https://doi.org//10.1016/j.molimm.2005.08.004
- https://doi.org//10.3109/15412555.2012.676110
- https://doi.org//10.4049/jimmunol.164.11.5866
- https://doi.org//10.1111/apm.12785
- https://doi.org//10.1038/srep17798
- https://doi.org//10.1016/j.amjms.2017.03.013
- https://doi.org//10.1016/j.imbio.2015.10.004
- https://doi.org//10.1172/JCI10124
- https://doi.org//10.1371/journal.pone.0085046
- https://doi.org//10.1164/rccm.201701-0225OC
- https://doi.org//10.1038/onc.2014.20
- https://doi.org//10.3389/fimmu.2018.01126
- https://doi.org//10.1593/neo.07112
- https://doi.org//10.1016/S1476-5586(04)80047-2
- https://doi.org//10.1007/s10549-016-4013-7
- https://doi.org//10.1038/nrc2088
- https://doi.org//10.1002/eji.200838302
- https://doi.org//10.1159/000451026
- https://doi.org//10.3389/fmed.2018.00018
- https://doi.org//10.1378/chest.08-0600
- https://doi.org//10.1038/onc.2017.253
- https://doi.org//10.3978/j.issn.2218-6751.2015.01.01
- https://doi.org//10.1074/jbc.M404296200
- https://doi.org//10.1038/1654
- https://doi.org//10.1016/j.cca.2015.01.023
- https://doi.org//10.1158/2159-8290.CD-11-0136
- https://doi.org//10.3748/wjg.v21.i31.9403
- https://doi.org//10.4049/jimmunol.174.11.6943
- https://doi.org//10.1007/s12307-011-0077-4
- https://doi.org//10.1136/jclinpath-2011-200355
- https://doi.org//10.4049/jimmunol.0901947
- https://doi.org//10.1038/ni.2703
- https://doi.org//10.1097/COC.0000000000000239
- https://doi.org//10.1016/j.cyto.2013.04.029
- https://doi.org//10.1016/j.it.2006.11.002
- https://doi.org//10.1189/jlb.3AB0213-092RR
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity